Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity

This article originally appeared here.
Share this content:
Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity
Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity

TUESDAY, Aug. 30, 2016 (HealthDay News) -- For acute major bleeding within 18 hours after factor Xa inhibitor administration, a bolus and infusion of andexanet alfa (andexanet) reduces factor Xa activity, according to a study published online Aug. 30 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 27 to 31 in Rome.

Stuart J. Connolly, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a multicenter trial involving 67 patients with acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients all received a bolus of andexanet followed by a two-hour infusion.

The researchers found that among patients receiving rivaroxaban and apixaban, the median anti-factor Xa activity decreased by 89 and 93 percent, respectively, from baseline after the bolus administration. During the two-hour infusion these levels remained similar. There was a relative decrease from baseline of 39 and 30 percent in the measure of anti-factor Xa activity at four hours after the end of the infusion for patients receiving rivaroxaban and apixaban, respectively. Clinical hemostasis was excellent or good at 12 hours after andexanet infusion in 79 percent of patients in the efficacy analysis.

"An initial bolus and subsequent two-hour infusion of andexanet substantially reduced anti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitors, with effective hemostasis occurring in 79 percent," the authors write.

The study was funded by Portola Pharmaceuticals, the developer of andexanet alfa.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Aspirin, Rivaroxaban Similar After Total Hip, Knee Arthroplasty

Aspirin, Rivaroxaban Similar After Total Hip, Knee Arthroplasty

Extended prophylaxis with aspirin no different from rivaroxaban for preventing venous thromboembolism

Odds of ARDS Up After Cardiac Surgery During Flu Season

Odds of ARDS Up After Cardiac Surgery During ...

Cardiac surgery during flu season is independent risk factor for acute respiratory distress syndrome

In A-Fib Patients, Stroke Risk Higher for Blacks Than Whites

In A-Fib Patients, Stroke Risk Higher for Blacks ...

Higher risk of ischemic stroke seen before, after atrial fibrillation diagnosis compared with whites

is free, fast, and customized just for you!

Already a member?

Sign In Now »